FDA fast-tracks psychedelic drug research following Trump executive order

The Food and Drug Administration announced on Friday a series of actions intended to accelerate the use of psychedelic treatments for serious mental illness, including fast-tracking research for approval to bring new drugs to market. The move from the FDA comes just six days after President Donald Trump signed an executive order on Saturday directing […]
Source
Washington Examiner
Opens original article in a new tab



